enGene raises $200M via oversubscribed private placement; CEO Hanson to resign for family/health reasons

enGene Therapeutics Inc.

Sold 20M shares at $10.00 each (31% premium to Feb 13 close); gross proceeds $200M; expected close Feb 16.
New and existing investors participated, including Adage, Blue Owl, Boxer, Cormorant, Deerfield, and Janus Henderson.
Proceeds to fund EG-70 pivotal study for BCG-unresponsive NMIBC; cash runway extends into 2027.
CEO Jason Hanson to resign upon successor appointment due to personal family/health reasons; Board initiated search.
Hanson will serve as Senior Strategic Advisor for at least six months post-resignation at $25,000/month.

item 1.01 item 3.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jason Hanson

Chief Executive Officer

ENGN · enGene Therapeutics Inc.

Filed: February 14, 2024, 6:59 PM ET

Mr. Hanson will resign from his positions as Chief Executive Officer of the Company and as a member of the Company’s Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason Hanson departed as Chief Executive Officer at enGene Therapeutics Inc..

Action: resign
Role: Chief Executive Officer

Exact text from the filing

Mr. Hanson will resign from his positions as Chief Executive Officer of the Company and as a member of the Company’s Board

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.96

enGene Therapeutics Inc. entered into Subscription Agreements with the investors named therein valued at approximately $200 million (effective 2024-02-13).

Action: entry
Agreement: equity purchase
Counterparty: the investors named therein
Value: approximately $200 million
Effective: 2024-02-13

Exact text from the filing

On February 13, 2024, enGene Holdings Inc. (the “ Company ”) entered into subscription agreements (collectively, the “ Subscription Agreements ”) with the investors named therein (the “ Investors ”), for the private placement (the “ Private Placement ”) of 20,000,000 common shares of the Company (the “ Subscribed Shares ”), at a price of $10.00 per share. The aggregate gross proceeds from the Private Placement are expected to be approximately $200 million, before deducting offering expenses.

View on SEC.gov

300 material agreements filed in the last 30 days. Browse all material agreements →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-035074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.